OBJECTIVE: Compare the initial phases of virologic decay when acute/early and advanced HIV-infected adults are administered the same treatment regimen. DESIGN: Mathematical modeling of a previously completed prospective treatment pilot study involving treatment-naive patients with early and advanced immunosuppression. METHODS: We analyzed data from a treatment protocol in which 18 individuals with acute or recent HIV-1 seroconversion and six patients with advanced AIDS were administered the same four-drug antiretroviral regimen. Initial treatment responses were compared by fitting a mathematical model to frequent viral load measurements in order to calculate the first and second phase kinetics of viral clearance, and also by comparing viral load suppression over 24 weeks. Patients were also comprehensively compared in terms of protease inhibitor drug levels, HIV-specific immune responses at baseline, and the presence of drug resistance-conferring mutations. RESULTS: There was no statistically meaningful difference in first phase clearance of comparable high-level viremia in the two groups, whether protease inhibitor levels were inserted into the model or 100% antiviral drug effectiveness was assumed. In contrast, acute/early patients had inferior sustained responses than advanced patients, reflecting erratic adherence. CONCLUSIONS: Despite many years of intervening immune destruction, the initial virologic decay on therapy appears to be the same at the extremes of the HIV disease spectrum.
OBJECTIVE: Compare the initial phases of virologic decay when acute/early and advanced HIV-infected adults are administered the same treatment regimen. DESIGN: Mathematical modeling of a previously completed prospective treatment pilot study involving treatment-naive patients with early and advanced immunosuppression. METHODS: We analyzed data from a treatment protocol in which 18 individuals with acute or recent HIV-1 seroconversion and six patients with advanced AIDS were administered the same four-drug antiretroviral regimen. Initial treatment responses were compared by fitting a mathematical model to frequent viral load measurements in order to calculate the first and second phase kinetics of viral clearance, and also by comparing viral load suppression over 24 weeks. Patients were also comprehensively compared in terms of protease inhibitor drug levels, HIV-specific immune responses at baseline, and the presence of drug resistance-conferring mutations. RESULTS: There was no statistically meaningful difference in first phase clearance of comparable high-level viremia in the two groups, whether protease inhibitor levels were inserted into the model or 100% antiviral drug effectiveness was assumed. In contrast, acute/early patients had inferior sustained responses than advanced patients, reflecting erratic adherence. CONCLUSIONS: Despite many years of intervening immune destruction, the initial virologic decay on therapy appears to be the same at the extremes of the HIV disease spectrum.
Authors: H Putter; J M Prins; S Jurriaans; M Roos; N M Ferguson; R van Praag; L van der Hoek; H Schuitemaker; R M Anderson; J Goudsmit; J M Lange; F de Wolf Journal: AIDS Date: 2000-12-22 Impact factor: 4.177
Authors: B Ramratnam; S Bonhoeffer; J Binley; A Hurley; L Zhang; J E Mittler; M Markowitz; J P Moore; A S Perelson; D D Ho Journal: Lancet Date: 1999-11-20 Impact factor: 79.321
Authors: Michael Louie; Christine Hogan; Michele Di Mascio; Arlene Hurley; Viviana Simon; James Rooney; Nancy Ruiz; Scott Brun; Eugene Sun; Alan S Perelson; David D Ho; Martin Markowitz Journal: J Infect Dis Date: 2003-03-06 Impact factor: 5.226
Authors: Daniel R Kuritzkes; Heather J Ribaudo; Kathleen E Squires; Susan L Koletar; Jorge Santana; Sharon A Riddler; Richard Reichman; Cecilia Shikuma; William A Meyer; Karin L Klingman; Roy M Gulick Journal: J Infect Dis Date: 2007-03-06 Impact factor: 5.226
Authors: Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw Journal: Nature Date: 2003-03-20 Impact factor: 49.962
Authors: G R Kaufmann; P Cunningham; A D Kelleher; J Zaunders; A Carr; J Vizzard; M Law; D A Cooper Journal: J Infect Dis Date: 1998-12 Impact factor: 5.226
Authors: Michele L Turner; Kedria Reed-Walker; Jennifer R King; Edward P Acosta Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2003-02-05 Impact factor: 3.205
Authors: M Altfeld; E S Rosenberg; R Shankarappa; J S Mukherjee; F M Hecht; R L Eldridge; M M Addo; S H Poon; M N Phillips; G K Robbins; P E Sax; S Boswell; J O Kahn; C Brander; P J Goulder; J A Levy; J I Mullins; B D Walker Journal: J Exp Med Date: 2001-01-15 Impact factor: 14.307
Authors: Toshiyuki Miura; Zabrina L Brumme; Mark A Brockman; Pamela Rosato; Jennifer Sela; Chanson J Brumme; Florencia Pereyra; Daniel E Kaufmann; Alicja Trocha; Brian L Block; Eric S Daar; Elizabeth Connick; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; Martin Markowitz; Kim Schafer; Florin Vaida; Aikichi Iwamoto; Susan Little; Bruce D Walker Journal: J Virol Date: 2010-05-26 Impact factor: 5.103
Authors: Tanzy M T Love; Sung Yong Park; Elena E Giorgi; Wendy J Mack; Alan S Perelson; Ha Youn Lee Journal: Bioinformatics Date: 2015-12-31 Impact factor: 6.937
Authors: Cynthia L Gay; Ashley J Mayo; Chelu K Mfalila; Haitao Chu; Anna C Barry; JoAnn D Kuruc; Kara S McGee; Melissa Kerkau; Joe Sebastian; Susan A Fiscus; David M Margolis; Charles B Hicks; Guido Ferrari; Joseph J Eron Journal: AIDS Date: 2011-04-24 Impact factor: 4.177
Authors: Jessie K Edwards; Stephen R Cole; Adaora Adimora; Jason Fine; Jeff Martin; Joseph Eron Journal: J Acquir Immune Defic Syndr Date: 2015-02-01 Impact factor: 3.731
Authors: Joseph K Wong; Matthew C Strain; Rodin Porrata; Elizabeth Reay; Sumathi Sankaran-Walters; Caroline C Ignacio; Theresa Russell; Satish K Pillai; David J Looney; Satya Dandekar Journal: PLoS Pathog Date: 2010-01-29 Impact factor: 6.823
Authors: Victor Y Du; Anju Bansal; Jonathan Carlson; Jesus F Salazar-Gonzalez; Maria G Salazar; Kristin Ladell; Stephanie Gras; Tracy M Josephs; Sonya L Heath; David A Price; Jamie Rossjohn; Eric Hunter; Paul A Goepfert Journal: J Immunol Date: 2016-03-16 Impact factor: 5.422